Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2023

Fair Value Disclosures [Abstract]

Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following tables summarize the assets measured at fair value on a recurring basis (in thousands):

	June 30, 2023
	Total		Level 1		Level 2		Level 3
Assets
Cash and cash equivalents:
Cash	$	19,244	$	19,244	$	—	$	—
Money market funds	110,622		110,622		—		—
Total cash and cash equivalents	129,866		129,866		—		—
Short-term investments:
U.S. Treasury bills	60,696		60,696		—		—
Corporate debt securities	12,819		—		12,819		—
Commercial paper	400,153		—		400,153		—
U.S. Agency bonds	175,900		—		175,900		—
Total short-term investments	649,568		60,696		588,872		—
Long-term investment:
ORIC Pharmaceuticals, Inc.	4,565		4,565		—		—
Total	$	783,999	$	195,127	$	588,872	$	—

	December 31, 2022
	Total		Level 1		Level 2		Level 3
Assets
Cash and cash equivalents:
Cash	$	53,033	$	53,033	$	—	$	—
Money market funds	174,262		174,262		—		—
U.S. Agency bonds	7,965		—		7,965		—
Total cash and cash equivalents	235,260		227,295		7,965		—
Short-term investments:
U.S. Treasury bills	221,362		221,362		—		—
Corporate debt securities	94,533		—		94,533		—
Commercial paper	442,743		—		442,743		—
U.S. Agency bonds	89,939		—		89,939		—
Total short-term investments	848,577		221,362		627,215		—
Long-term investment:
ORIC Pharmaceuticals, Inc.	3,465		3,465		—		—
Total	$	1,087,302	$	452,122	$	635,180	$	—

Schedule of Changes in Estimated Fair Value of Assets with Unobservable Inputs

The following table represents the change in estimated fair value of and transfer activity for the Company’s Level 3 investment (in thousands):

Balance as of December 31, 2021	$	8,218
Change in fair value at lock-up expiration	(3,100)
Transfer from Level 3 to Level 1 at lock-up expiration	(5,118)
Balance as of March 31, 2022	$	—